Development of new anti-cancer drugs
- 37 Downloads
In the first award lecture of the European Society of Medical Oncology (ESMO) the topic of new drug development and the role of the European Organization for Research and Treatment of Cancer (EORTC) was highlighted. New aspects in each of the drug development steps are discussed: acquisition, screening, formulation, toxicology and phase I studies. In the search for new compounds to treat human solid tumors it is proposed to use human tumors as xenografts in primary screening. Phenomena related to doxorubicin resistance are presented together with a new approach to circumvent this in the clinic. The value of biochemical modulation is discussed, exemplified by the combination of 5-fluorouracil and uridine. The complexity of the biological response modifiers and the importance of evaluating them adequately in the clinic is stressed. The EORTC has recently decided on requirements for the minimum toxicology for phase I trials of a new cytostatic drug in order to ensure safe and rapid evaluation of new anti-cancer compounds. The therapeutic intents of phase I studies are questionable and therefore the main goals of these studies to be reached quickly; possibly supported by a pharmacokinetic rational.
Key wordsDevelopment Anti-cancer drugs
Unable to display preview. Download preview PDF.
- 2.Golding A, Venditti J M, MacDonald J S, Muggia F M, Henney J E and DeVita V T: Current results of the screening program at the division of cancer treatment, National Cancer Institute.Eur J Cancer 17, 129 (1981).Google Scholar
- 3.NCI planning to switch drug development emphasis from compound to human cancer oriented strategy.Cancer Lett 10, 1–3 (1984).Google Scholar
- 5.Martin D S, Balis M E, Frei E, Goldin A, Heppner G H, Holland J F, Houghton J A, Houghton P J, Johnson R K, Mittelman A, Rustum Y, Sawyer R C, Schmid F A, Stolfi R L, Young C W: The role of murine tumor models in cancer treatment research. Presented at the Work Shop on Disease Oriented Antitumor Drug Discovery and Development, NCI, Bethesda, MD, U.S.A., 9–10 January (1985).Google Scholar
- 6.DCT Board approves new screening program, natural product concepts.Cancer Lett 11, 4–6 (1985)Google Scholar
- 13.Braakhuis B J M, Snow G B: Current therapy series (In press)Google Scholar
- 14.Boven E: Human ovarian cancer xenografts in nude mice. Application of a new model in the selection of novel agents for ovarian cancer. Rodopi, Amsterdam (1986).Google Scholar
- 18.Peters G J, van Dijk J, van Groeningen C, Laurensse E J, Leyva A, Lankelma J, Pinedo H M: Toxicity and antitumor effects of 5-fluorouracil and its rescue by uridine, in:Purine and Pyrimidine Metabolism in Man, V, Part B, 121 (1986).Google Scholar
- 25.Lelieveld P, Velzen D van, Vijgh W J F van der, Klein I, Pinedo H M, Putten L M van: Toxicology of 5 platinum derivatives in dogs.Invest New Drugs 2, 101 (1984).Google Scholar
- 26.Collins J M, Zaharko D S, Dedrick R L, Chabner B A: Potential roles for preclinical pharmacology in phase I trials.Cancer Treatment Rep 70, 73 (1986).Google Scholar